Extensive functional profiling of the covalent CB1 allosteric probe GAT100 across multiple signaling pathways confirmed it as a more potent and cleaner negative allosteric modulator than existing compounds, with critical structural insights.
Read this if you follow CB1 receptor allosteric modulator research or cannabinoid drug development.
GAT100 outperformed all existing CB1 allosteric modulators across every assay
What the researchers found
Building on the initial discovery of GAT100 (RTHC-01201), this study comprehensively characterized its effects across an array of downstream signaling pathways.
GAT100 functioned as a negative allosteric modulator of the orthosteric agonist CP55,940 and the endocannabinoids 2-AG and anandamide across multiple readouts: beta-arrestin1 recruitment, PLCbeta3 and ERK1/2 phosphorylation, cAMP accumulation, and CB1 receptor internalization.
Critically, GAT100 was more potent and effective than both Org27569 and PSNCBAM-1 (the two most-studied CB1 allosteric modulators) in every assay tested. It also lacked the inverse agonism associated with those earlier compounds, a significant advantage for drug development.
Computational docking studies identified C7.38(382) as a key structural feature of GAT100's binding to the allosteric site, providing critical information for designing next-generation allosteric drugs.
Why it matters
This comprehensive profiling establishes GAT100 as the gold-standard tool for studying CB1 allosteric modulation and provides the detailed signaling data needed to guide drug design. The identification of the key binding residue is a breakthrough for rational drug development.
The numbers in context
GAT100 tested across 5+ signaling pathways. More potent and efficacious than Org27569 and PSNCBAM-1 in all assays. No inverse agonism. C7.38(382) identified as critical binding residue. Active in both overexpression and endogenous CB1 expression systems.
How the study worked
Multi-assay functional profiling in HEK293A cells overexpressing CB1R and in Neuro2a and STHdhQ7/Q7 cells endogenously expressing CB1R. Assessed beta-arrestin1 recruitment, PLCbeta3 phosphorylation, ERK1/2 phosphorylation, cAMP accumulation, and receptor internalization. Computational docking studies identified key binding residues.
What this study cannot tell us
All data are from cell-based systems. In vivo validation is needed. The covalent nature of GAT100 limits its therapeutic potential but enhances its value as a research tool. Endogenous expression systems used different cell types that may not fully reflect neuronal CB1 biology.
How to read the evidence
Thorough in vitro characterization across multiple cell systems and signaling pathways, with computational structural insights. No in vivo data.
When this study was published
Published in 2016. GAT100 has become a widely used research tool in cannabinoid pharmacology.
The bigger picture
This work represents a critical step from basic discovery toward translational application. By thoroughly characterizing GAT100's signaling profile and identifying structural determinants, the study provides the roadmap for engineering the next generation of CB1 allosteric drugs.
Questions still open
- Can reversible analogs of GAT100 be designed that retain its improved pharmacological profile? Will the C7.38(382) binding site be confirmed by crystallography or cryo-EM? How does allosteric modulation of CB1 affect behavior in animal models?
Common questions
What makes GAT100 better than previous CB1 allosteric modulators?
How does this help develop new medicines?
Read the original research
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
ACS chemical neuroscience, 7(6), 776-98
Citation
Laprairie, Robert B; Kulkarni, Abhijit R; Kulkarni, Pushkar M; Hurst, Dow P; Lynch, Diane; Reggio, Patricia H; Janero, David R; Pertwee, Roger G; Stevenson, Lesley A; Kelly, Melanie E M; Denovan-Wright, Eileen M; Thakur, Ganesh A. (2016). Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.. ACS chemical neuroscience, 7(6), 776-98. https://doi.org/10.1021/acschemneuro.6b00041
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)